Pre-made Exbivirumab benchmark antibody (Whole mAb, anti-HBV (hepatitis B virus) surface antigen (HBsAg) [Hepatitis B virus] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-848

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Product Details

Anti-HBV (hepatitis B virus) surface antigen (HBsAg) [Hepatitis B virus] therapeutic antibody (Pre-made Exbivirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Exbivirumab is a human monoclonal antibody[1] developed for the treatment of hepatitis B infections.[2]

Products Name (INN Index)

Pre-Made Exbivirumab Biosimilar, Whole Mab: Anti-Hbv (Hepatitis B Virus) Surface Antigen (Hbsag) [Hepatitis B Virus] therapeutic antibody

INN Name

exbivirumab

Target

HBV (hepatitis B virus) surface antigen (HBsAg) [Hepatitis B virus]

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1 – lambda

VD LC

IgG1 – lambda

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Cubist Pharmaceuticals, Inc. (Lexington MA USA) / XTL Biopharmaceuticals (Herzliya Israel)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

HBV (hepatitis B virus) surface antigen (HBsAg) [Hepatitis B virus]

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide